Navigation Links
Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey
Date:10/31/2011

PRINCETON, N.J., Oct. 31, 2011 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that its central laboratory services ranked first, by a wide margin, in an independent global survey of 550 physician investigators participating in clinical trials. The majority (54 percent) of the study participants named Covance central laboratory services as their "most preferred" central laboratory, with investigators citing Covance three times more often than the nearest competitor.  Investigators also reported having the "best overall relationship" with Covance, rating it 8.4 on a scale of 1 to 10.  

The survey also determined that investigators who participate in a clinical trial with their preferred central laboratory are overwhelmingly satisfied (98 percent). When pharmaceutical sponsors select investigators' least preferred central laboratory, satisfaction drops significantly. Respondents cited central laboratory preference as a key driver of satisfaction with the pharmaceutical sponsor as well, with more than 85 percent of investigators stating that they are more satisfied and willing to work with a sponsor on trials when they have selected their preferred central laboratory.  Ninety-four percent of investigators indicate the central laboratory selected by the sponsor impacts their (and their staffs') success, day-to-day activities, and willingness to work with a particular sponsor on future studies.

Survey results showed that factors that lead to a strong relationship between investigators and a central laboratory include effective communication, the laboratory's reputation for reliability and quality, and easy-to-use collection kits. Respondents ranked Covance first in all of the key performance metrics, from customer service to timely and accurate reporting.

"We make every effort to understand the challenges investigators face and tailor our operations to overcome those challenges," said Jon Koch, Corporate Vice President and President, Central Laboratory Services. "Our ongoing dialogue with the investigator community has allowed us to make their priorities our priorities – and this study demonstrates that our efforts are recognized and valued among investigators across the globe."

Covance, the most experienced provider of clinical trial central laboratory services in the world, has five dedicated laboratories in the United States, Switzerland, Singapore, China and Japan.  In the past five years alone, Covance central laboratories have conducted more than 197 million laboratory tests for more than 3,600 clinical trial protocols in more than 95 countries, working with more than 115,000 investigator sites.

The "Clinical Trial Investigator Satisfaction and Central Laboratory Performance" survey, conducted earlier this month by the Life Science Strategy Group, questioned physicians actively participating in pharmaceutical industry-sponsored clinical trials as investigators. Participants were prescreened to ensure a high level of involvement and/or key decision-making authority for their investigative site. All global geographies and practice settings were represented, as were more than 20 medical specialties. The mean experience level in a clinical trial setting was 13.4 years.

To learn more about the study or to download sample pages from the report, visit www.lifesciencestrategy.com.

About Covance Inc.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.9 billion, global operations in more than 30 countries, and more than 10,500 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
2. Covance Receives Highest Level of Phase I Accreditation
3. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2009 Financial Results Conference Call
4. Covance to Present at the 28th Annual J.P. Morgan Healthcare Conference
5. Rules-Based Medicine Forms Biomarker Alliance With Covance Inc.
6. Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
7. Covance to Present at Piper Jaffray 21st Annual Health Care Conference
8. Covance To Present At The 20th Annual Global Healthcare Services Conference
9. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
10. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
11. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):